A 6-year-old spayed female Boxer presents with a rapidly ...

Thank you for reaching out, doctor. A rapidly growing, erythematous, pruritic mass with mast cells on cytology in a Boxer raises a high suspicion for a cutaneous mast cell tumor (MCT), which is unfortunately a common and often aggressive neoplasm in this breed. The pruritus can be due to histamine release from the mast cells.

Before we can formulate a definitive treatment plan, comprehensive staging and accurate grading are paramount.

Current Staging Guidelines for Canine Cutaneous Mast Cell Tumors

The goal of staging is to determine the extent of the disease (local, regional, or distant spread) to guide prognosis and treatment.

Histopathology with Surgical Biopsy/Excision (CRITICAL): While cytology provides a presumptive diagnosis, histopathology is essential for definitive diagnosis and, most importantly, grading.

* Patnaik Grading System (I, II, III): This is the traditional system. Grade I and II tumors generally have a better prognosis than Grade III.
* Kiupel Two-Tier Grading System (Low vs. High Grade): This newer system is gaining favor due to its stronger prognostic correlation. It classifies tumors as "low-grade" or "high-grade" based on mitotic index, presence of multinucleated cells, bizarre nuclei, and karyomegaly. High-grade tumors carry a significantly worse prognosis, with a median survival time often less than 4 months if not treated aggressively.
* Proliferation Indices: Immunohistochemical stains for Ki-67 and AgNOR counts can provide additional prognostic information, especially for intermediate-grade tumors, helping to identify those that may behave more aggressively.

Regional Lymph Node Aspiration: This is non-negotiable for any MCT. The regional lymph node should always be aspirated, even if it feels normal on palpation. Cytology of the aspirate can detect metastatic mast cells. If positive, further workup and potentially more aggressive therapy are indicated. A histopathologic biopsy of the lymph node is ideal if surgery is performed.

Abdominal Imaging (Ultrasound):

* Spleen and Liver: These are common sites for visceral metastasis or systemic spread. An abdominal ultrasound should be performed to assess the size, architecture, and presence of any masses or diffuse changes in the spleen and liver. Fine-needle aspirates (FNAs) of any suspicious lesions should be collected.
* Other Abdominal Lymph Nodes: Evaluate for enlargement, particularly the mesenteric lymph nodes.

Thoracic Radiographs (Three-View): While pulmonary metastasis from cutaneous MCTs is rare, thoracic radiographs are part of the standard staging protocol to rule out obvious distant spread to the lungs or mediastinal lymphadenopathy.

Complete Blood Count (CBC), Serum Chemistry Panel, Urinalysis: These are general health screens to assess overall patient health, rule out paraneoplastic syndromes (e.g., GI ulceration from histamine release), and ensure the patient is a candidate for anesthesia and chemotherapy. A buffy coat smear can be performed to look for circulating mast cells, but its sensitivity is low, and it's not always indicative of widespread disease. Bone marrow aspiration is generally reserved for cases with cytopenias, circulating mast cells, or suspicion of systemic disease.

Recommended Treatment Options Based on Grade and Stage

Treatment for MCTs is multimodal, combining surgery, radiation, and/or chemotherapy, tailored to the grade and stage of the tumor.

1. Surgery (Primary Modality):
* Wide and Deep Excision: For cutaneous MCTs, a surgical plan aiming for 2-3 cm lateral margins and one fascial plane deep is recommended for complete excision. This often requires reconstructive techniques, especially on the flank.
* Histopathology of Excised Tumor: Critical for confirming complete margins and providing the definitive grade (Patnaik or Kiupel).

2. Adjuvant Therapy (Post-Surgery):

* Low-Grade (Patnaik Grade I/II, Kiupel Low-Grade) with Complete Excision (Stage I):
* Surgery alone is often curative.
* Monitor closely for recurrence.

* Low-Grade with Incomplete Margins (Stage I):
* Re-excision: If anatomically feasible, this is the preferred option.
* Adjuvant Radiation Therapy: If re-excision is not possible or declined, radiation therapy to the surgical site is highly effective in achieving local control. Definitive radiation protocols (15-20 fractions) are typically used.

* High-Grade (Patnaik Grade III, Kiupel High-Grade) Regardless of Margins (Stage II/III/IV), or any Grade with Regional Lymph Node Metastasis (Stage III):
* These tumors have a high metastatic potential and require systemic therapy.
* Adjuvant Chemotherapy:
* Toceranib (Palladia): A multi-targeted tyrosine kinase inhibitor. It is effective, especially in tumors with c-KIT mutations (which predict response, though not required for use). The VERIFIED DRUG FORMULARY dose is toceranib 2.5-2.75 mg/kg PO every other day. Monitor for GI side effects, proteinuria (check UPC), neutropenia, and hepatotoxicity. Dose reduction is commonly needed.
* Vinblastine/Prednisone: A traditional combination protocol. Vinblastine is given weekly, combined with prednisone.
* Vincristine: Note, the formulary has vincristine (0.7 mg/m² IV Weekly per protocol) for lymphoma, but vinblastine is typically used for MCTs. If vinblastine is not available or desired, lomustine (canine: 70-90 mg/m² PO Every 3-4 weeks) is another option, often combined with prednisone.
* Prednisone: Prednisone 2 mg/kg then taper PO Daily then taper per protocol. Prednisone has anti-inflammatory and cytotoxic effects on mast cells.
* Lomustine (CCNU): Another effective single agent for high-grade MCTs, especially those that have failed other protocols. The VERIFIED DRUG FORMULARY dose for canine is lomustine 70-90 mg/m² PO every 3-4 weeks. Monitor CBC and liver enzymes before each dose due to cumulative hepatotoxicity.
* Adjuvant Radiation Therapy: If margins are incomplete, radiation should be considered in addition to chemotherapy for local control.

* Distant Metastasis (Stage IV):
* The prognosis is guarded. Treatment focuses on palliative care and systemic chemotherapy.
* Toceranib, lomustine, or vinblastine/prednisone can be used to manage systemic disease.
* Metronomic Chemotherapy: Low-dose continuous cyclophosphamide (cyclophosphamide 10-15 mg/m²/day PO) combined with piroxicam (piroxicam 0.3 mg/kg PO Daily) can be considered for long-term maintenance or as a palliative option, leveraging its anti-angiogenic properties.

3. c-KIT Mutation Status:
* Testing for c-KIT mutations (e.g., exon 11 tandem duplications) can be helpful, as these mutations predict a better response to tyrosine kinase inhibitors like toceranib.

In summary, for your patient, the next crucial steps are surgical excision of the mass with wide margins, followed by histopathology with appropriate grading, and a thorough staging workup including regional lymph node aspiration and abdominal ultrasound. Based on these findings, we can then determine the most appropriate adjuvant therapy to offer the best quality of life and prognosis.